Related Experiment Video
Updated: Feb 15, 2026

Isolation, Cryopreservation and Culture of Human Amnion Epithelial Cells for Clinical Applications
Published on: December 21, 2014
Acute or Delayed Systemic Administration of Human Amnion Epithelial Cells Improves Outcomes in Experimental Stroke
Megan A Evans1, Rebecca Lim1, Hyun Ah Kim1
1From the Departments of Pharmacology (M.A.E., H.A.K., H.X.C., C.V.G.-M., K.W.E.T., C.T.C., V.H.B., S.L., Q.N.D., A.V., G.R.D., C.G.S., B.R.S.B.), Obstetrics and Gynaecology (R.L., E.M.W.), Surgery (A.V., G.R.D., C.G.S.), and Medicine (T.G.P., V.K.S.), Australian Regenerative Medicine Institute (W.K., L.T., J.A.B.), and Monash Institute of Pharmaceutical Sciences (C.P.J.H., C.W.P., J.M.H.), Monash University, Victoria, Australia; Department of Physiology, Anatomy and Microbiology, La Trobe University, Victoria, Australia (M.A.E., H.A.K., Q.N.D., A.V., G.R.D., C.G.S.); The Ritchie Centre, Hudson Institute of Medical Research, Victoria, Australia (R.L., E.M.W.); Stroke Unit (T.G.P., V.K.S., H.M.) and Monash Women's Services (E.M.W.), Monash Health, Victoria, Australia; Menzies Research Institute, Tasmania, Australia (V.K.S.); Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (T.V.A., D.Y.F., L.P.); School of Pharmacy, Sungkyunkwan University, Seoul, South Korea (T.V.A.); School of Health and Biomedical Sciences, RMIT University, Victoria, Australia (S.S.); Department of Anatomy, Brain Health Research Centre and Brain Research New Zealand (S.N., E.K.G., A.N.C.) and Department of Pathology (S.N.;S.Y.;A.N.C.), University of Otago, Dunedin, New Zealand; and Faculty of Pharmacy, University of Sydney, NSW, Australia (A.N.C.).
Background And Purpose:
Human amnion epithelial cells (hAECs) are nonimmunogenic, nontumorigenic, anti-inflammatory cells normally discarded with placental tissue. We reasoned that their profile of biological features, wide availability, and the lack of ethical barriers to their use could make these cells useful as a therapy in ischemic stroke.
Methods:
We tested the efficacy of acute (1.5 hours) or delayed (1-3 days) poststroke intravenous injection of hAECs in 4 established animal models of cerebral ischemia. Animals included young (7-14 weeks) and aged mice (20-22 months) of both sexes, as well as adult marmosets of either sex.
Results:
We found that hAECs administered 1.5 hours after stroke in mice migrated to the ischemic brain via a CXC chemokine receptor type 4-dependent mechanism and reduced brain inflammation, infarct development, and functional deficits. Furthermore, if hAECs administration was delayed until 1 or 3 days poststroke, long-term functional recovery was still augmented in young and aged mice of both sexes. We also showed proof-of-principle evidence in marmosets that acute intravenous injection of hAECs prevented infarct development from day 1 to day 10 after stroke.
Conclusions:
Systemic poststroke administration of hAECs elicits marked neuroprotection and facilitates mechanisms of repair and recovery.
Related Concept Videos
Oral Drug Delivery Systems: Delayed-Release Systems
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Predicting Reaction Outcomes
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Second Order systems II
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

